LINEAGE-LOGISTICS,-LLC
8.2.2023 06:51:25 CET | Business Wire | Press release
Lineage Logistics, LLC (“Lineage” or the “Company”), one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide, announced Lineage Fresh, a new strategic service in Europe, launched last November in the US, which provides fresh storage solutions for major importers, grocers, and producers of fresh fruit and produce, as part of its participation in the Fruit Logistica trade show in Berlin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207006000/en/
Fresh blueberries are packed at a Lineage facility. (Photo: Business Wire)
Lineage Fresh will allow products with a short shelf-life to face fewer obstacles, less risk, and less spoilage with Lineage’s cold storage technology and leading logistics network. Leveraging the Company’s expertise as a global temperature-controlled storage provider, Lineage Fresh is designed to cater to businesses in which food safety is critical and speed to market is essential. The new value-added services and specialized capabilities of Lineage Fresh include re-pack & bagging services, reconditioning, restacking, restyling, container plugs, multi-temperature zones for produce, cold treatment, fumigation, container drayage, juice processing and blending, and the integration of customs’ bonded facilities.
“Lineage Fresh brings state-of-the-art fresh capacity and product expertise to our expanding European network, and connects the growing fresh produce market with customers across Europe and the world,” said Edwin Wentink, Vice President, Business Development Europe. “Lineage Fresh capitalises on the investments we have made in Kloosterboer Group’s legacy of fresh product expertise and its class leading facilities in Rotterdam and Vlissingen, along with a growing footprint in Southern Europe. We are excited to highlight this new solution as part of our participation in Fruit Logistica in Berlin this year.”
Fresh produce importers, exporters, and the international fresh fruit and vegetable community at large have been experiencing significant service and capacity issues with their fresh products. To address Lineage customers’ needs, Lineage has made significant investment in the space to meet the demands of the fresh market and to create a truly connected ‘fresh’ network.
- In Europe, over the past two years, Lineage has focused on value-added services needed to handle fresh fruits and vegetables, namely fresh food storage, repacking, bagging, and transportation. The Company started this venture in June 2021 with the acquisition of Kloosterboer Group, which continues to bring a large, long-standing fresh operation to the Lineage network, with fresh facilities in both Rotterdam and Vlissingen.
- In December 2021, Lineage acquired Sun Valley Cold Storage and its facility in Swedesboro, N.J., expanding its presence in the U.S. Tri-State area, where 80% of U.S. produce enters the country. Sun Valley Cold Storage served the fresh produce market for more than 15 years, with a team of experienced professionals dedicated to handling fresh fruits and vegetables. Lineage is in the process of expanding this facility with 5,000 additional pallets coming online in Q1 2023, leveraging the capacity and expertise of the former Sun Valley and Kloosterboer operations to enhance Lineage’s fresh network globally.
- Lineage is building a new, state-of-the-art refrigerated storage facility at the port of Savannah, Ga., expected to open in February 2023, completely dedicated to fresh produce. Savannah is the fastest-growing port and largest single container terminal in North America, and the new facility will help cut through port congestion to ensure fewer obstacles in maintaining the freshness of the produce.
To learn more about Lineage Fresh, or to find out how you can partner with Lineage, click here.
About Lineage Logistics
Lineage Logistics is one of the leading temperature-controlled industrial REIT and logistics solutions providers worldwide. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 20 countries across North America, Europe, and Asia-Pacific. Lineage has industry-leading expertise in end-to-end logistical solutions, an unrivaled real estate network, and develops and deploys innovative technology. This helps increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, helps feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 3 in the 2022 CNBC Disruptor 50 list, named a Deloitte US Best Managed Company in 2022, the No. 1 Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change the World list in 2020. (www.lineagelogistics.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207006000/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom